---
title: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in
  lung adenocarcinoma
date: '2024-06-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38866964/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240613182215&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: KRAS/TP53 co-mutation predicts ICI benefit in univariate
  and multivariate survival analyses and is associated with unique molecular tumour
  features. Mutation testing of the two genes can be easily implemented using small
  NGS ...'
disable_comments: true
---
CONCLUSIONS: KRAS/TP53 co-mutation predicts ICI benefit in univariate and multivariate survival analyses and is associated with unique molecular tumour features. Mutation testing of the two genes can be easily implemented using small NGS ...